A Bayesian adaptive design for two-stage clinical trials with survival data

Area of Science:

• Biostatistics
• Clinical Trial Design
• Bayesian Inference

Background:

• Phase III clinical trials require robust designs for patient allocation and treatment comparison.
• Survival time is a critical endpoint in many clinical studies.
• Traditional single-stage designs may lack flexibility in adaptive settings.

Purpose of the Study:

• To propose and evaluate a novel two-stage adaptive Bayesian design for phase III clinical trials.
• To assess the performance of this design in terms of patient allocation and treatment comparison.
• To compare the proposed adaptive design with a standard single-stage randomized procedure.

Main Methods:

• A two-stage adaptive Bayesian design framework was developed.
• The design incorporates survival time as the primary treatment response.
• Numerical and theoretical analyses were conducted to study the design's properties.
• The proposed design was compared against a single-stage randomized design.

Main Results:

• The proposed adaptive Bayesian design demonstrates specific exact and limiting properties.
• Performance metrics of the adaptive design were evaluated.
• Comparisons revealed potential advantages over single-stage designs.
• The methodology's practical application was illustrated with real-world data.

Conclusions:

• The developed two-stage adaptive Bayesian design is a viable and potentially superior approach for phase III clinical trials.
• This design offers enhanced flexibility and efficiency in patient allocation and treatment evaluation.
• The findings support the use of adaptive Bayesian methods in clinical research for survival endpoints.